Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Mandatory Filings Under CFIUS New Rules

Client Alert

On September 15, 2020, the Committee on Foreign Investment in the United States (“CFIUS”) promulgated a final rule modifying its mandatory declaration requirements for certain foreign investment transactions involving “TID US businesses” (sensitive U.S. businesses dealing in critical technologies, critical infrastructure and sensitive personal data) dealing in “critical technologies” – i.e., U.S. businesses that produce, design, test, manufacture, fabricate, or develop one or more critical technologies. The new rule also makes amendments to the definition of the term “substantial interest” (used to determine whether a foreign government has a substantial interest in an entity). The final rule became effective on October 15, 2020.

For background purposes, CFIUS is an interagency committee authorized to review certain transactions involving foreign investment in the United States and certain real estate transactions by foreign persons, in order to determine the effect of such transactions on the national security of the United States. 

The new rule renders it critical for parties to a potentially covered transaction to conduct due diligence with legal counsel regarding the classification of the technology of a U.S. company under export control laws.

Prior to the new rule, filings were mandatory for covered transactions involving 27 sensitive industries (31 C.F.R. Part 801 – Annex A). [i] By eliminating the requirement that the critical technology falls within one of 27 industries identified by CFIUS, a filing will now be required for a covered transaction involving a TID US business that deals in critical technologies for which a “U.S. regulatory authorization” would be required to export, re-export, transfer (in-country) or retransfer the technologies to a certain foreign person.

Under the former rule, a foreign government would have a substantial interest in an entity with a general partner (or managing member or equivalent) if the foreign government held a 49% or greater interest (either voting or economic) in the general partner. Under the new rule, this requirement pertains to instances where the activities of the entity are primarily directed, controlled, or coordinated by or on behalf of the general partner. Note that a general partner is deemed to direct, control, or coordinate such activities by contracting a third party to perform such services.

The new rule clarifies how indirect interests in a general partner (or managing member or equivalent) will be calculated. Under the current rule, for purposes of calculating substantial interest, a parent is deemed to hold 100% of only the voting interest of its subsidiary. Under the new rule, a parent will be deemed to hold 100% of the voting and economic interest of its subsidiary.

CFIUS filing is mandatory when a foreign person (a) makes a direct investment, or acquires a direct interest, in a U.S. business that is a covered transaction in a U.S. critical technology business or (b) individually holds, or is part of a group of foreign persons that in the aggregate holds, a direct or indirect 25% or more voting interest in the foreign investor identified in clause (a). If the foreign investor is a partnership that is controlled by a general partner, then the 25% share referenced in clause (b) is based on the foreign person’s share in the general partner. A parent is deemed to own 100% of the interest held by its subsidiary. 

Based on the foregoing, it will be important for a U.S. company contemplating a potentially covered transaction to review with legal counsel the effects of the new CFIUS rule.

If you have questions regarding CFIUS filing, please contact Robert Q. Lee at rqlee@bmdpl.com.

[i] (31 C.F.R. Part 801 – Annex A) 

List of Pilot Program Industries 1. Aircraft Manufacturing (NAICS Code: 336411) 2. Aircraft Engine and Engine Parts Manufacturing (NAICS Code: 336412) 3. Alumina Refining and Primary Aluminum Production (NAICS Code: 331313) 4. Ball and Roller Bearing Manufacturing (NAICS Code: 332991) 5. Computer Storage Device Manufacturing (NAICS Code: 334112) 6. Electronic Computer Manufacturing (NAICS Code: 334111) 7. Guided Missile and Space Vehicle Manufacturing (NAICS Code: 336414) 8. Guided Missile and Space Vehicle Propulsion Unit and Propulsion Unit Parts Manufacturing (NAICS Code: 336415) 9. Military Armored Vehicle, Tank, and Tank Component Manufacturing (NAICS Code: 336992) 10. Nuclear Electric Power Generation (NAICS Code: 221113) 11. Optical Instrument and Lens Manufacturing (NAICS Code: 333314) 12. Other Basic Inorganic Chemical Manufacturing (NAICS Code: 325180) 13. Other Guided Missile and Space Vehicle Parts and Auxiliary Equipment Manufacturing (NAICS Code: 336419) 14. Petrochemical Manufacturing (NAICS Code: 325110) 15. Powder Metallurgy Part Manufacturing (NAICS Code: 332117) 16. Power, Distribution, and Specialty Transformer Manufacturing (NAICS Code: 335311) 17. Primary Battery Manufacturing (NAICS Code: 335912) 18. Radio and Television Broadcasting and Wireless Communications Equipment Manufacturing (NAICS Code: 334220) 19. Research and Development in Nanotechnology (NAICS Code: 541713) 20. Research and Development in Biotechnology (except Nanobiotechnology) (NAICS Code: 541714) 21. Secondary Smelting and Alloying of Aluminum (NAICS Code: 331314) 22. Search, Detection, Navigation, Guidance, Aeronautical, and Nautical System and Instrument Manufacturing (NAICS Code: 334511) 23. Semiconductor and Related Device Manufacturing (NAICS Code: 334413) 24. Semiconductor Machinery Manufacturing (NAICS Code: 333242) 25. Storage Battery Manufacturing (NAICS Code: 335911) 26. Telephone Apparatus Manufacturing (NAICS Code: 334210) 27. Turbine and Turbine Generator Set Units Manufacturing (NAICS Code: 333611)


Exposure to COVID-19 Flow Chart

Exposure to COVID-19 Flow Chart

Lessons Learned: Five Tips for Buying or Selling a Practice

If you are anticipating buying or selling a practice during the coming months, you are not alone. The healthcare industry is experiencing a wave of integration. In fact, it has been occurring for several years. Many transactional healthcare attorneys have negotiated and closed dozens of these transactions for clients. They have negotiated on behalf of the sellers in some cases and the buyers in others.

Ramping Up – A Quick Guide to Pressing COVID-19 Employment Law Issues

As the country continues to grapple with a global pandemic that now seems to be never-ending, businesses everywhere are waking up to realize that the calming of the COVID-19 employment issues over the summer has come to an end. As cases rise exponentially in all 50 states as we head into the winter months, the number of employment issues related to COVID-19 will also increase dramatically. For these reasons, it is important that we return to the employment law basics that were covered this prior spring, while highlighting the many lessons we have learned along the way. As COVID-19 matters and concerns continue to hinder the working environment of every business, it is important that you reference this review to guide you through these tough issues and questions.

Your Workplace Under Biden

This is my favorite recurring post – Predictions of How a New Administration Will Affect Your Workplace. Four years ago, we accurately called the emasculation of the 2016 proposed FLSA Overtime Rules (the salary exemption threshold was set at $35,568 in 2019, rather than $47,476 as proposed), we forecasted a conservative shift of the NLRB and its results (a roll-back of employee rights, social media policy evaluations, and joint employer rules), and we nailed the likelihood of multiple conservative appointments to the United States Supreme Court and its long-term effects (although I completely failed to predict that my ND classmate Amy Coney Barrett would fill the final vacancy during the Trump administration). This time, the L+E Practice of BMD has decided to make it a group effort at predicting what will happen, what probably happen, and what might happen under President Biden. As always, please save this in your important files and pull it out four (or eight) years from now to judge our accuracy.

HHS Provider Relief Funds Reporting Requirements: Important Updates Every Provider Should Know

HHS continues to revise its reporting requirements for the use of the Provider Relief Funds. Providers with more than $10,000 in Provider Relief Fund payments must report on the use of the funds through December 31, 2020. The reporting window will begin on January 15, 2021 and providers must complete reporting obligations for FY 2020 by February 15, 2021 through a portal designed by HHS. However, providers that have unexpended funds as of December 31, 2020, will have an additional 6 months to use the remaining funds through June 30, 2021. These providers must submit a second and final report no later than July 31, 2021.